Chapter/Section Purchase

1 Study Coverage
1.1 Relapsed Acute Myeloid Leukemia Drug Product Introduction
1.2 Market by Type
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Market by Application
1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region
2.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022)
2.4.2 Global Sales Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
2.5 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
2.5.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022)
2.5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
3.1.1 Global Top Relapsed Acute Myeloid Leukemia Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Relapsed Acute Myeloid Leukemia Drug in 2021
3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
3.2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Relapsed Acute Myeloid Leukemia Drug Revenue in 2021
3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales by Type (2017-2022)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type
4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022)
4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application
5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales by Application (2017-2022)
5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application
5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application
5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022)
5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
6.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
6.1.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
6.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
6.2.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
6.2.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
6.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
6.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
6.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Type
7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
7.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Application
7.2.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
7.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
7.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
7.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
7.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Type
8.1.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Application
8.2.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Region
8.3.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
9.1.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
9.1.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
9.2 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
9.2.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
9.2.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
9.3 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
9.3.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
9.3.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Type
10.1.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Application
10.2.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country
10.3.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 4SC AG
11.1.1 4SC AG Corporation Information
11.1.2 4SC AG Overview
11.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 4SC AG Recent Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Corporation Information
11.2.2 AbbVie Inc. Overview
11.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AbbVie Inc. Recent Developments
11.3 Actinium Pharmaceuticals, Inc.
11.3.1 Actinium Pharmaceuticals, Inc. Corporation Information
11.3.2 Actinium Pharmaceuticals, Inc. Overview
11.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Actinium Pharmaceuticals, Inc. Recent Developments
11.4 Agios Pharmaceuticals, Inc.
11.4.1 Agios Pharmaceuticals, Inc. Corporation Information
11.4.2 Agios Pharmaceuticals, Inc. Overview
11.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Agios Pharmaceuticals, Inc. Recent Developments
11.5 Amgen Inc.
11.5.1 Amgen Inc. Corporation Information
11.5.2 Amgen Inc. Overview
11.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Amgen Inc. Recent Developments
11.6 Arog Pharmaceuticals, Inc.
11.6.1 Arog Pharmaceuticals, Inc. Corporation Information
11.6.2 Arog Pharmaceuticals, Inc. Overview
11.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Arog Pharmaceuticals, Inc. Recent Developments
11.7 Array BioPharma Inc.
11.7.1 Array BioPharma Inc. Corporation Information
11.7.2 Array BioPharma Inc. Overview
11.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Array BioPharma Inc. Recent Developments
11.8 Astellas Pharma Inc.
11.8.1 Astellas Pharma Inc. Corporation Information
11.8.2 Astellas Pharma Inc. Overview
11.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Astellas Pharma Inc. Recent Developments
11.9 Astex Pharmaceuticals, Inc.
11.9.1 Astex Pharmaceuticals, Inc. Corporation Information
11.9.2 Astex Pharmaceuticals, Inc. Overview
11.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Astex Pharmaceuticals, Inc. Recent Developments
11.10 AstraZeneca Plc
11.10.1 AstraZeneca Plc Corporation Information
11.10.2 AstraZeneca Plc Overview
11.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 AstraZeneca Plc Recent Developments
11.11 AVEO Pharmaceuticals, Inc.
11.11.1 AVEO Pharmaceuticals, Inc. Corporation Information
11.11.2 AVEO Pharmaceuticals, Inc. Overview
11.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AVEO Pharmaceuticals, Inc. Recent Developments
11.12 BioLineRx, Ltd.
11.12.1 BioLineRx, Ltd. Corporation Information
11.12.2 BioLineRx, Ltd. Overview
11.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 BioLineRx, Ltd. Recent Developments
11.13 Boehringer Ingelheim GmbH
11.13.1 Boehringer Ingelheim GmbH Corporation Information
11.13.2 Boehringer Ingelheim GmbH Overview
11.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Boehringer Ingelheim GmbH Recent Developments
11.14 Boston Biomedical, Inc.
11.14.1 Boston Biomedical, Inc. Corporation Information
11.14.2 Boston Biomedical, Inc. Overview
11.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Boston Biomedical, Inc. Recent Developments
11.15 Bristol-Myers Squibb Company
11.15.1 Bristol-Myers Squibb Company Corporation Information
11.15.2 Bristol-Myers Squibb Company Overview
11.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Bristol-Myers Squibb Company Recent Developments
11.16 Calithera Biosciences, Inc.
11.16.1 Calithera Biosciences, Inc. Corporation Information
11.16.2 Calithera Biosciences, Inc. Overview
11.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Calithera Biosciences, Inc. Recent Developments
11.17 Celgene Corporation
11.17.1 Celgene Corporation Corporation Information
11.17.2 Celgene Corporation Overview
11.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Celgene Corporation Recent Developments
11.18 Cornerstone Pharmaceuticals, Inc.
11.18.1 Cornerstone Pharmaceuticals, Inc. Corporation Information
11.18.2 Cornerstone Pharmaceuticals, Inc. Overview
11.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
11.19 CTI BioPharma Corp.
11.19.1 CTI BioPharma Corp. Corporation Information
11.19.2 CTI BioPharma Corp. Overview
11.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 CTI BioPharma Corp. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Relapsed Acute Myeloid Leukemia Drug Industry Chain Analysis
12.2 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
12.4 Relapsed Acute Myeloid Leukemia Drug Sales and Marketing
12.4.1 Relapsed Acute Myeloid Leukemia Drug Sales Channels
12.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors
12.5 Relapsed Acute Myeloid Leukemia Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
13.2 Relapsed Acute Myeloid Leukemia Drug Market Drivers
13.3 Relapsed Acute Myeloid Leukemia Drug Market Challenges
13.4 Relapsed Acute Myeloid Leukemia Drug Market Restraints
14 Key Findings in The Global Relapsed Acute Myeloid Leukemia Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer